Published in Int J Exp Pathol on October 29, 2010
N-terminal truncated intracellular matrix metalloproteinase-2 induces cardiomyocyte hypertrophy, inflammation and systolic heart failure. PLoS One (2013) 0.94
Prevalence of coronary artery ectasia in older adults and the relationship with epicardial fat volume by cardiac computed tomography angiography. J Geriatr Cardiol (2013) 0.92
A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity. PLoS One (2012) 0.92
Among Ectasia Patients with Coexisting Coronary Artery Disease, TIMI Frame Count Correlates with Ectasia Size and Markis Type IV Is the Commonest. Cardiol Res Pract (2015) 0.77
Aneurysmal coronary artery disease. Circulation (1983) 5.58
Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest (2002) 4.79
Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol (2007) 3.19
Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol (2006) 3.02
Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol (1995) 3.00
Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol (1998) 1.90
Fate of nonobstructive aneurysmatic coronary artery disease: angiographic and clinical follow-up report. Am Heart J (1985) 1.67
Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol (2002) 1.66
Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol (2006) 1.63
Novel insights into an old controversy: is coronary artery ectasia a variant of coronary atherosclerosis? Clin Res Cardiol (2007) 1.56
Coronary artery ectasia--is it time for a reappraisal? Clin Cardiol (2007) 1.45
Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation (2001) 1.43
Coronary artery ectasias: imaging, functional assessment and clinical implications. Eur Heart J (2006) 1.38
Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res (2005) 1.30
Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochem Biophys Res Commun (2007) 1.23
Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem (2003) 1.19
Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am J Physiol Heart Circ Physiol (2006) 1.12
Coronary arterial ectasia: increased prevalence in patients with abdominal aortic aneurysm as compared to occlusive atherosclerotic peripheral vascular disease. Am Heart J (1993) 1.05
Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis (2005) 1.02
Matrix metalloproteinase-2: the forgotten enzyme in aneurysm pathogenesis. Ann N Y Acad Sci (2006) 1.01
Remodeling of the vascular tunica media is essential for development of collateral vessels in the canine heart. Mol Cell Biochem (2004) 0.96
Temporal association between circulating proteolytic, inflammatory and neurohormonal markers in patients with coronary ectasia. Atherosclerosis (2004) 0.91
Frequency of coronary artery ectasia in patients undergoing surgery for ascending aortic aneurysms. Am J Cardiol (2004) 0.87
Is any link between inflammation and coronary artery ectasia? Med Hypotheses (2007) 0.81
Second hand smoke stimulates tumor angiogenesis and growth. Cancer Cell (2003) 2.17
Doxorubicin cardiomyopathy. Cardiology (2009) 1.99
A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. Cardiovasc Res (2007) 1.91
Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol (2003) 1.83
Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol (2006) 1.63
Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J (2006) 1.59
Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. J Biol Chem (2001) 1.51
Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. Am J Physiol Heart Circ Physiol (2007) 1.50
Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol (2002) 1.45
Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation (2004) 1.44
Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol (2006) 1.43
Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res (2005) 1.30
A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J (2003) 1.29
Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochem Biophys Res Commun (2007) 1.23
Matrix metalloproteinases in vascular physiology and disease. Vascular (2012) 1.22
Differences among cell types in NAD(+) compartmentalization: a comparison of neurons, astrocytes, and cardiac myocytes. J Neurosci Res (2007) 1.22
Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart. J Biochem Mol Toxicol (2007) 1.21
Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem (2003) 1.19
Moderate alcohol consumption induces sustained cardiac protection by activating PKC-epsilon and Akt. Am J Physiol Heart Circ Physiol (2002) 1.16
Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre- and postconditioning. Am J Physiol Heart Circ Physiol (2009) 1.16
Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc Res (2007) 1.13
Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am J Physiol Heart Circ Physiol (2006) 1.12
Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury. Med Sci Monit (2006) 1.11
The effect of gradual or acute arterial occlusion on skeletal muscle blood flow, arteriogenesis, and inflammation in rat hindlimb ischemia. J Vasc Surg (2005) 1.11
The prodomain of interleukin 1alpha interacts with elements of the RNA processing apparatus and induces apoptosis in malignant cells. FASEB J (2003) 1.08
Transcription factor YB-1 mediates DNA polymerase alpha gene expression. J Biol Chem (2004) 1.07
Sphingosine can pre- and post-condition heart and utilizes a different mechanism from sphingosine 1-phosphate. J Biochem Mol Toxicol (2008) 1.07
Combined sphingosine, S1P and ischemic postconditioning rescue the heart after protracted ischemia. Biochem Biophys Res Commun (2008) 1.07
Ischaemic postconditioning protects isolated mouse hearts against ischaemia/reperfusion injury via sphingosine kinase isoform-1 activation. Cardiovasc Res (2008) 1.07
High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate. Am J Physiol Heart Circ Physiol (2010) 1.07
Effect of anoxia/reperfusion on the reversible active/de-active transition of NADH-ubiquinone oxidoreductase (complex I) in rat heart. Biochim Biophys Acta (2002) 1.07
Molecular determinants of responses to myocardial ischemia/reperfusion injury: focus on hypoxia-inducible and heat shock factors. Cardiovasc Res (2004) 1.06
A rapid radioassay for sphingosine kinase. Anal Biochem (2005) 1.02
S1P lyase: a novel therapeutic target for ischemia-reperfusion injury of the heart. Am J Physiol Heart Circ Physiol (2011) 1.02
Intronic regulation of matrix metalloproteinase-2 revealed by in vivo transcriptional analysis in ischemia. Proc Natl Acad Sci U S A (2005) 1.00
Pyrroloquinoline quinone preserves mitochondrial function and prevents oxidative injury in adult rat cardiac myocytes. Biochem Biophys Res Commun (2007) 0.99
Combinatorial interactions of p53, activating protein-2, and YB-1 with a single enhancer element regulate gelatinase A expression in neoplastic cells. J Biol Chem (2002) 0.99
Associations of interleukin-6, C-reactive protein and serum amyloid A with mortality in haemodialysis patients. Nephrology (Carlton) (2008) 0.99
Evaluation of Akt/mTOR activity in muscle atrophy after rotator cuff tears in a rat model. J Orthop Res (2012) 0.98
Redox-dependent change of nucleotide affinity to the active site of the mammalian complex I. Biochemistry (2007) 0.97
Comparison of pyrroloquinoline quinone and/or metoprolol on myocardial infarct size and mitochondrial damage in a rat model of ischemia/reperfusion injury. J Cardiovasc Pharmacol Ther (2006) 0.96
Intraventricular and interventricular cellular heterogeneity of inotropic responses to α(1)-adrenergic stimulation. Am J Physiol Heart Circ Physiol (2013) 0.95
The disintegrin domain of ADAM9: a ligand for multiple beta1 renal integrins. Biochem J (2005) 0.95
MnSOD in mouse heart: acute responses to ischemic preconditioning and ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol (2005) 0.95
Protein kinase C epsilon dependence of the recovery from down-regulation of S1P1 G protein-coupled receptors of T lymphocytes. J Biol Chem (2003) 0.95
N-terminal truncated intracellular matrix metalloproteinase-2 induces cardiomyocyte hypertrophy, inflammation and systolic heart failure. PLoS One (2013) 0.94
Acute vincristine pretreatment protects adult mouse cardiac myocytes from oxidative stress. J Mol Cell Cardiol (2007) 0.94
Overexpression of endothelial nitric oxide synthase increases skeletal muscle blood flow and oxygenation in severe rat hind limb ischemia. J Vasc Surg (2003) 0.94
Interleukin-1 gene cluster polymorphisms predict risk of ESRD. Kidney Int (2005) 0.93
Cardiomyocyte S1P1 receptor-mediated extracellular signal-related kinase signaling and desensitization. J Cardiovasc Pharmacol (2009) 0.93
Sphingolipid signaling and treatment during remodeling of the uninfarcted ventricular wall after myocardial infarction. Am J Physiol Heart Circ Physiol (2009) 0.93
Vincristine attenuates doxorubicin cardiotoxicity. Biochem Biophys Res Commun (2008) 0.93
A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity. PLoS One (2012) 0.92
Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease. Cardiovasc Pathol (2008) 0.92
Low dose N, N-dimethylsphingosine is cardioprotective and activates cytosolic sphingosine kinase by a PKCepsilon dependent mechanism. Cardiovasc Res (2006) 0.91
mTOR regulates fatty infiltration through SREBP-1 and PPARγ after a combined massive rotator cuff tear and suprascapular nerve injury in rats. J Orthop Res (2012) 0.91
A sphingosine kinase form 2 knockout sensitizes mouse myocardium to ischemia/reoxygenation injury and diminishes responsiveness to ischemic preconditioning. Oxid Med Cell Longev (2011) 0.90
Effect of oxygen on activation state of complex I and lack of oxaloacetate inhibition of complex II in Langendorff perfused rat heart. FEBS Lett (2004) 0.90
Epinephrine is required for normal cardiovascular responses to stress in the phenylethanolamine N-methyltransferase knockout mouse. Circulation (2007) 0.89
A biomechanical analysis of venous tissue in its normal and post-phlebitic conditions. J Biomech (2010) 0.88
Pyrroloquinoline quinone (PQQ) decreases myocardial infarct size and improves cardiac function in rat models of ischemia and ischemia/reperfusion. Cardiovasc Drugs Ther (2004) 0.88
Adult cardiac fibroblasts null for sphingosine kinase-1 exhibit growth dysregulation and an enhanced proinflammatory response. J Mol Cell Cardiol (2007) 0.88
Differential transcriptional activation of matrix metalloproteinase-2 and membrane type-1 matrix metalloproteinase by experimental deep venous thrombosis and thrombin. J Vasc Surg (2005) 0.88
Adeno-associated viral vector-mediated gene transfer of VEGF normalizes skeletal muscle oxygen tension and induces arteriogenesis in ischemic rat hindlimb. Mol Ther (2003) 0.87
Therapeutic angiogenesis for critical limb ischemia: invited commentary. J Control Release (2002) 0.87
A novel strong competitive inhibitor of complex I. FEBS Lett (2005) 0.87
Altering pyrroloquinoline quinone nutritional status modulates mitochondrial, lipid, and energy metabolism in rats. PLoS One (2011) 0.87
Minocycline protects cardiac myocytes against simulated ischemia–reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1. J Cardiovasc Pharmacol (2010) 0.87
Tumour metastasis suppressor, nm23-beta, inhibits gelatinase A transcription by interference with transactivator Y-box protein-1 (YB-1). Biochem J (2002) 0.86
Original article Muscle extracellular matrix degradation and contractibility following tendon rupture and disuse. Muscles Ligaments Tendons J (2013) 0.86
Regulation of MMP-2 gene transcription in dermal wounds. J Invest Dermatol (2007) 0.85
Inhibition of MMP2/MMP9 after spinal cord trauma reduces apoptosis. Spine (Phila Pa 1976) (2008) 0.84
Expression of a Gi-coupled receptor in the heart causes impaired Ca2+ handling, myofilament injury, and dilated cardiomyopathy. Am J Physiol Heart Circ Physiol (2007) 0.84
An angiotensin converting enzyme haplotype predicts survival in patients with end stage renal disease. Hum Genet (2006) 0.83
Telomerase deficiency in bone marrow-derived cells attenuates angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol (2010) 0.83
Therapeutic angiogenesis. Vasc Endovascular Surg (2007) 0.83
Correlation of a simple direct measurement of muscle pO(2) to a clinical ischemia index and histology in a rat model of chronic severe hindlimb ischemia. J Vasc Surg (2002) 0.83
Molecular characterization of post-thrombotic syndrome. J Vasc Surg (2007) 0.82
Sphingolipids in cardiovascular and cerebrovascular systems: Pathological implications and potential therapeutic targets. World J Cardiol (2013) 0.82
Myocardial survival signaling in response to stem cell transplantation. J Am Coll Surg (2009) 0.81
Lipid signalling in cardiovascular pathophysiology. Cardiovasc Res (2009) 0.81
Role of redox signaling and poly (adenosine diphosphate-ribose) polymerase activation in vascular smooth muscle cell growth inhibition by nitric oxide and peroxynitrite. J Vasc Surg (2008) 0.81
Mechanisms of matrix metalloproteinase-2 (mmp-2) transcriptional repression by progesterone in jar choriocarcinoma cells. Reprod Biol Endocrinol (2009) 0.80
Polymeric meshes induce zonal regulation of matrix metalloproteinase-2 gene expression by macrophages and fibroblasts. FASEB J (2007) 0.79
Cardioprotective activity of a novel and potent competitive inhibitor of lactate dehydrogenase. FEBS Lett (2010) 0.79
Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors. Surgery (2010) 0.78
Sustained preconditioning induced by cardiac transgenesis with the tetracycline transactivator. Am J Physiol Heart Circ Physiol (2005) 0.78
Role of AP-1 and RE-1 binding sites in matrix metalloproteinase-2 transcriptional regulation in skeletal muscle atrophy. Biochem Biophys Res Commun (2010) 0.78
Transcription factor Ets-1 regulates gelatinase a gene expression in mesangial cells. J Am Soc Nephrol (2002) 0.78
The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf (2012) 0.78